These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 33805422)

  • 21. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia.
    Christodoulou I; Solomou EE
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.
    Albinger N; Müller S; Kostyra J; Kuska J; Mertlitz S; Penack O; Zhang C; Möker N; Ullrich E
    Bone Marrow Transplant; 2024 Apr; 59(4):489-495. PubMed ID: 38253870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK cell defects: implication in acute myeloid leukemia.
    D'Silva SZ; Singh M; Pinto AS
    Front Immunol; 2023; 14():1112059. PubMed ID: 37228595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations.
    Garg S; Ni W; Griffin JD; Sattler M
    Hematol Rep; 2023 Nov; 15(4):608-626. PubMed ID: 37987319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

  • 31. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
    Fiorenza S; Turtle CJ
    BioDrugs; 2021 May; 35(3):281-302. PubMed ID: 33826079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.
    Arora S; Asawa P; Ramakrishnan A; Bachier C; Majhail NS
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):159-167. PubMed ID: 36537907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T cell therapy in AML: recent progress and future perspectives.
    Saito S; Nakazawa Y
    Int J Hematol; 2024 Jul; ():. PubMed ID: 38963636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
    Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
    Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.